Sarepta Therapeutics Inc Investor Relations Material
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. The Company's product candidates include eteplirsen (EXONDYS 51), an exon-skipping agent that is used in treating Duchenne muscular dystrophy (DMD), drisapersen (MIRAGE) for the treatment of moderate to severe hypoactive sexual desire disorder (HSDD) associated with female hypoactive sexual desire disorder (FHSDD); and drisapersen for the treatment of DMD. The Company has collaboration agreements with with several other biopharmaceutical companies.
Latest company events
More about Sarepta Therapeutics Inc
Ticker symbol
SRPT
Country
United States of America
About the company
Investor Relations Page
Dig deeper into the Sarepta Therapeutics Inc fundamentals on Quartr.
- Conference calls from all over the world
- Search for anything across all transcripts
- Consensus estimates
- Comprehensive financial data
- Read the transcripts or scroll the deck
- Slide decks and earnings reports
